COMMUNIQUÉS West-GlobeNewswire

Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity
09/01/2026
PLANEGG, Germany and MUNICH, Jan. 09, 2026 (GLOBE NEWSWIRE) -- A new study published in Pharmaceutics ( https://doi.org/10.3390/pharmaceutics18010050 ) shows that LEON’s FR-JET ® modular mixer addresses key [...]
Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer
09/01/2026
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
09/01/2026
Company to present Tuesday, January 13 th at 10:00 a.m. PT / 1:00 p.m. ET GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix [...]
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
09/01/2026
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient [...]
Medicines360 Acquires Global Licensing Rights to Innovative Maternal Health Technologies for Risk Identification and Management Throughout Pregnancy
09/01/2026
Licensing of scientific discoveries from University of Cambridge and University of Edinburgh is aimed to speed translation and access to life-saving diagnostics for women worldwide. SAN FRANCISCO, Jan. 09, 2026 (GLOBE [...]
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
09/01/2026
Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapies DGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra ® (resmetirom) for potential additive [...]
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
09/01/2026
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single [...]
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
09/01/2026
Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for [...]
Clene Announces Registered Direct Offering of Over $28 Million
09/01/2026
Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo Capital Initial financing tranche of over $6 million [...]
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
09/01/2026
-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of [...]
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
09/01/2026
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
09/01/2026
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort [...]
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
09/01/2026
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an [...]
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium
09/01/2026
New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE WOODLANDS, TX, Jan. [...]
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
09/01/2026
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- PDS [...]
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
09/01/2026
Live panel presentation on Tuesday, January 13th at 8:00 AM PT SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company [...]
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
09/01/2026
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today provided additional context [...]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Alamar Biosciences for the Transformative Bio-Hermes Studies
09/01/2026
WASHINGTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation ® (GAP) is pleased to welcome Alamar Biosciences , a company powering precision proteomics to enable the earliest detection of [...]
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
09/01/2026
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates [...]

Pages